Photo: Close up of researcher using a pippette


MIS416 is a therapy currently in phase 2 trials for secondary progressive MS. It is being developed by Innate Immunotherapeutics.

In July 2017 researchers reported that MIS416 didn't show any benefits for people with secondary progressive MS. The company has announced that they will fully analyse the data before considering the next steps for the drug.

Current phase of trial: Phase 2

Type of MS: Secondary progressive MS

Find out more about MIS416